Evidence map›Paper›PMID 42581971›Full record

ArticleFrontiers in oncology2026

Case Report: Locally advanced primary esophageal melanoma with early brain metastasis.

Huixin Yu, Shuo Sun, Xianfeng Lu, Xunjie Kuang, Yi Duan, Mingfang Xu, Xiao Yang, Mengxia Li

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Huixin YuDepartment of Cancer Center, Daping Hospital, Army Medical University, Chongqing, China.
Shuo SunDepartment of Cancer Center, Daping Hospital, Army Medical University, Chongqing, China.
Xianfeng LuDepartment of Cancer Center, Daping Hospital, Army Medical University, Chongqing, China.
Xunjie KuangDepartment of Cancer Center, Daping Hospital, Army Medical University, Chongqing, China.
Yi DuanDepartment of Cancer Center, Daping Hospital, Army Medical University, Chongqing, China.
Mingfang XuDepartment of Cancer Center, Daping Hospital, Army Medical University, Chongqing, China.
Xiao YangDepartment of Cancer Center, Daping Hospital, Army Medical University, Chongqing, China.
Mengxia LiDepartment of Cancer Center, Daping Hospital, Army Medical University, Chongqing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Primary malignant melanoma of the esophagus (PMME) is a rare malignancy of the esophagus. The main treatment is esophagectomy, but the recurrence and metastasis rate are very high, and the prognosis is very poor. Here, we report a case of locally advanced PMME that rapidly developed intracranial metastases after surgery and adjuvant therapy. Case presentation: The patient was a 47-year-old male with dysphagia. Endoscopy revealed multiple cauliflower-like lesions in the middle esophagus, confirmed as malignant melanoma via biopsy with positive immunohistochemical staining for SOX-10 and Melan-A, with regional lymph node metastases. The patient was diagnosed with PMME and was treated with radical esophagectomy. The adjuvant therapy used tislelizumab combined with lenvatinib. Five months after surgery, follow-up magnetic resonance imaging (MRI) indicated multiple intracranial metastases. The patient underwent a tumor resection of the left cerebellar lesion, and stereotactic radiosurgery for other lesions, and received oral temozolomide. One month after radiotherapy, his condition deteriorated rapidly, showing systemic progression, and he eventually passed away ten months after diagnosis. Conclusion: Despite surgical resection and adjuvant therapy, this case of PMME rapidly progressed with multiple intracranial metastases, highlighting the highly aggressive nature and poor prognosis of this malignancy.

Indexed as

adjuvant therapycase reportesophagectomyimmunotherapyprimary malignant melanoma of the esophagus (PMME)

Identifiers

PMID42581971
PMCPMC13457006

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.